ParkourSC

Activities: Digital Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

Cloudleaf announces rebrand to ParkourSC

The company has also just closed a $26m investment round, which will support its real-time supply chain platform
Ingredients

Scaling-up the pharmaceutical supply chain with digitisation: part II

To optimise their efficiency and profitability, next-generation supply chains must be built on a foundation of optimal visibility, Mahesh Veerina, CEO of Cloudleaf, tells Dr Kevin Robinson. Digitalisation tools that provide context, condition, timing and location data of materials and assets may play a crucial role in ensuring the safe and secure distribution of a COVID-19 vaccine
Digital

Scaling-up the pharmaceutical supply chain with digitisation: part I

If there are issues with any vaccine, the traditional recall process, which is highly dependent on manual and paper-based processes — and provides no insight in terms of where the product ends up — is not up to the task. It is simply too slow and ill-informed to combat the fallout!
Subscribe now